slides · global inventory
Compare Peers
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 9,820
Current window 6,931-6,960
Pages 328
Rows per page 30
Slide function
6,931-6,960 of 9,820
16
The chart uses a dual-axis approach to imply a safety-efficacy trade-off, positioning vedolizumab as the 'safest' and highly effective.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
17
The slide uses a checkmark/empty circle matrix to highlight competitive differentiation.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
22
Uses YTE modification as a mechanism for half-life extension.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
23
The slide uses a visual timeline/comparison to contrast the competitor's high-frequency, citrate-containing formulation with the company's low-frequency, citrate-free formulation.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
27
Uses historical peer data (Morphic, Prometheus) to project value inflection points for SPY001.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
28
The slide uses a comparison table to establish competitive positioning.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
31
The chart uses a horizontal bar format to compare clinical remission percentages across different drug targets (TL1A, a4b7, IL-23s, TNFa, S1P1s, JAKs).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
32
The slide uses a checkmark matrix to highlight the superiority of SPY002.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
34
Includes visual representation of antibody binding mechanisms.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
40
The chart uses a waterfall-style logic to show the additive effect of the combination therapy.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
41
The slide uses donut charts to represent remission rates and highlights the safety advantages of gut-selective backbones.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Evidence1 hit
49
The chart uses a custom range bar (min/max) with markers for IPO and Today's market cap.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Action1 hit
09
The chart shows a clear divergence between CPF's deposit costs and the peer average, particularly in recent periods.Central Pacific Financial | Results Presentation Deck | 19 slides · Central Pacific Financial
Conference presentation Investor relations Beat · Financials1 hit
12
Uses medical diagnostic criteria (DSM) to frame the business opportunity by analogy.Dare Bioscience | Investor Presentation Deck | 27 slides · Daré Bioscience
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
05
The slide uses a contrast-pairs framework to differentiate the company's core offering from the incumbent market standard.Deliveroo | Investor Event Presentation Deck | 27 slides · Deliveroo
Conference presentation Investor relations Beat · Problem1 hit
13
Deliveroo | Investor Event Presentation Deck | 27 slidesDeliveroo | Investor Event Presentation Deck | 27 slides · Deliveroo
Conference presentation Investor relations Loop · Why Now1 hit
40
The table uses a color-coded heatmap (green/yellow/red) to indicate performance against criteria.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
47
The slide uses a traffic-light color coding system (green/yellow/red) to visualize performance metrics.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
53
The slide uses a color-coded heatmap (green/yellow/red/grey) to visualize performance against target product profile (TPP) criteria.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
08
The slide uses a bar chart to compare hazard ratios of multiple compounds against a vehicle control, with statistical significance markers.NeuroSense Therapeutics | Investor Presentation Deck | 34 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
22
Includes both M&A transaction details and public market capitalization data for peer companies.OKYO Pharma | Results Presentation Deck | 25 slides · OKYO Pharma
Conference presentation Investor relations 1 hit
19
Uses donut charts to visualize the split between 3rd party supplier and vertically-integrated manufacturing.Proterra | Investor Presentation Deck | 25 slides · Proterra
Pitch deck Investor relations 1 hit
11
The slide uses a visual bridge to emphasize the delta between the two indices.Sarissa Capital | Activist Presentation Deck | 95 slides · Sarissa Capital
Activist deck Activist investor Beat · Expose ContradictionLoop · Logic Chain1 hit
12
The slide uses a visual gap analysis to emphasize the underperformance of ALKS relative to its peers.Sarissa Capital | Activist Presentation Deck | 95 slides · Sarissa Capital
Activist deck Activist investor Beat · Expose ContradictionLoop · Logic Chain1 hit
13
The chart uses a visual bridge to emphasize the performance delta between the indices and ALKS.Sarissa Capital | Activist Presentation Deck | 95 slides · Sarissa Capital
Activist deck Activist investor Beat · Expose ContradictionLoop · Logic Chain1 hit
27
Sarissa Capital | Activist Presentation Deck | 95 slidesSarissa Capital | Activist Presentation Deck | 95 slides · Sarissa Capital
Activist deck Activist investor Beat · Expose Contradiction1 hit
31
The chart uses red arrows to emphasize the valuation gap between Alkermes and larger peers.Sarissa Capital | Activist Presentation Deck | 95 slides · Sarissa Capital
Activist deck Activist investor Beat · Expose ContradictionLoop · Analogy1 hit
28
The chart uses a stacked bar format to compare depreciation and out-of-pocket expenses.VinFast | Investor Presentation Deck | 42 slides · VinFast
Pitch deck Investor relations 1 hit
40
The slide uses a broken-axis bar chart for manufacturing capacity to accommodate Tesla's significantly higher volume.VinFast | Investor Presentation Deck | 42 slides · VinFast
Pitch deck Investor relations 1 hit
41
Includes a break in the Y-axis for the first chart to accommodate the high Lucid value.VinFast | Investor Presentation Deck | 42 slides · VinFast
Pitch deck Investor relations 1 hit